title: Results of a large retrospective analysis of the effect of intended dose intensity of R-CHOP on outcome in a cohort of consecutive, unselected elderly patients with de novo diffuse large B cell lymphoma.
authors.affiliation: Department of Haematology, Oxford University Hospitals NHS Trust, Oxford, UK. toby.eyre@ouh.nhs.uk.
authors.forename: Toby A
authors.initials: TA
authors.lastname: Eyre
authors.affiliation: Department of Haematology, Oxford University Hospitals NHS Trust, Oxford, UK.
authors.forename: Richard
authors.initials: R
authors.lastname: Salisbury
authors.affiliation: Nuffield Department of Medicine, University of Oxford, Oxford, UK.
authors.forename: David W
authors.initials: DW
authors.lastname: Eyre
authors.affiliation: Department of Haematology, Oxford University Hospitals NHS Trust, Oxford, UK.
authors.forename: Caroline
authors.initials: C
authors.lastname: Watson
authors.affiliation: Department of Haematology, Oxford University Hospitals NHS Trust, Oxford, UK.
authors.forename: Graham P
authors.initials: GP
authors.lastname: Collins
authors.affiliation: Department of Haematology, Oxford University Hospitals NHS Trust, Oxford, UK.
authors.forename: Chris S
authors.initials: CS
authors.lastname: Hatton
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D015331:Cohort Studies; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007239:Infections / Q000139:chemically induced; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000401:mortality; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D012189:Retrospective Studies; D012307:Risk Factors; D000069283:Rituximab; D015996:Survival Rate; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
keywords: DLBCL; R-CHOP; dose intensity; elderly